Non-Small Cell Lung Cancer (NSCLC) Clinical Trials

⁃ The main inclusion criteria include but are not limited to the following:

• Has a histological or cytological diagnosis of locally advanced, unresected Stage II (node-positive) to III non-small cell lung cancer (NSCLC) with predominantly nonsquamous histology.

• Has completed definitive platinum-based concurrent chemoradiotherapy (CCRT) prior to enrollment, without disease progression.

• Has provided a tumor tissue sample for central laboratory testing of Kirsten rat sarcoma G12C (KRAS G12C) status, programmed cell death ligand 1 (PD-L1) status, and biomarker research.

• Tumor tissue sample has a demonstrated presence of KRAS G12C mutation and an evaluable PD-L1 status result.

• If human immunodeficiency virus (HIV)-infected, has well-controlled HIV on antiretroviral therapy (ART).

• If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy.

• If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.

• Has a body weight ≥35 kg.